Clinical Use of Bone Turnover Markers

被引：24

作者：

Bauer, Douglas C. ^{[1
]}

机构：

[1] Univ Calif San Francisco, 1545 16th St,Second Floor, San Francisco, CA 94143 USA

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2019年 / 322卷 / 06期

关键词：

PREDICTION; FRACTURE;

D O I：

10.1001/jama.2019.9372

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This JAMA Insights Clinical Update reviews bone turnover markers measurable in blood and urine and summarizes evidence supporting their use to predict osteoporosis and osteoporotic fractures, assess treatment adherence and efficacy, and monitor bone loss after drug discontinuation.

引用

页码：569 / 570

页数：2

共 9 条

[1] Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial [J].

Bauer, DC ;

Black, DM ;

Garnero, P ;

Hochberg, M ;

Ott, S ;

Orloff, J ;

Thompson, DE ;

Ewing, SK ;

Delmas, PD .

JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) :1250-1258

[2] Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy The FLEX Study [J].

Bauer, Douglas C. ;

Schwartz, Ann ;

Palermo, Lisa ;

Cauley, Jane ;

Hochberg, Marc ;

Santora, Art ;

Cummings, Steven R. ;

Black, Dennis M. .

JAMA INTERNAL MEDICINE, 2014, 174 (07) :1126-1134

[3] Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups [J].

Burch, Jane ;

Rice, Stephen ;

Yang, Huiqin ;

Neilson, Aileen ;

Stirk, Lisa ;

Francis, Roger ;

Holloway, Paul ;

Selby, Peter ;

Craig, Dawn .

HEALTH TECHNOLOGY ASSESSMENT, 2014, 18 (11) :1-+

[4] Use of bone turnover markers in postmenopausal osteoporosis [J].

Eastell, Richard ;

Szulc, Pawel .

LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (11) :908-923

[5] A Meta-Analysis of Reference Markers of Bone Turnover for Prediction of Fracture [J].

Johansson, Helena ;

Oden, Anders ;

Kanis, John A. ;

McCloskey, Eugene V. ;

Morris, Howard A. ;

Cooper, Cyrus ;

Vasikaran, Samuel .

CALCIFIED TISSUE INTERNATIONAL, 2014, 94 (05) :560-567

[6] Official Positions for FRAX® Clinical Regarding Biochemical Markers [J].

McCloskey, Eugene V. ;

Vasikaran, Samuel ;

Cooper, Cyrus .

JOURNAL OF CLINICAL DENSITOMETRY, 2011, 14 (03) :220-222

[7] Laboratory reproducibility of biochemical markers of bone turnover in clinical practice [J].

Schafer, A. L. ;

Vittinghoff, E. ;

Ramachandran, R. ;

Mahmoudi, N. ;

Bauer, D. C. .

OSTEOPOROSIS INTERNATIONAL, 2010, 21 (03) :439-445

[8] Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability [J].

Szulc, P. ;

Naylor, K. ;

Hoyle, N. R. ;

Eastell, R. ;

Leary, E. T. .

OSTEOPOROSIS INTERNATIONAL, 2017, 28 (09) :2541-2556

[9] Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards [J].

Vasikaran, S. ;

Eastell, R. ;

Bruyere, O. ;

Foldes, A. J. ;

Garnero, P. ;

Griesmacher, A. ;

McClung, M. ;

Morris, H. A. ;

Silverman, S. ;

Trenti, T. ;

Wahl, D. A. ;

Cooper, C. ;

Kanis, J. A. .

OSTEOPOROSIS INTERNATIONAL, 2011, 22 (02) :391-420

← 1 →